Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

• Status: Recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arcus Biosciences, Inc.
• Collaborator: Gilead Sciences
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLC

• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1

• At least one measurable target lesion per RECIST v1.1.

• Adequate organ and marrow function

• Participants must be willing to provide adequate tumor tissue

Exclusion Criteria:

• Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous

• Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).

• Concurrent chronic medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded).

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.